Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6068)
All Articles published online
|
Publishing Process of This Article
|
Jul 21, 2014 (publication date) through Mar 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liu Y, Wei R, Hong TP. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(27): 9090-9097 [PMID: 25083081 DOI: 10.3748/wjg.v20.i27.9090] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i27/9090.htm |
| Number | Citing Articles |
| 1 |
Xiaotong Kong, Jianjian Wang, Yuze Cao, Xiaoyu Lu, Huixue Zhang, XiaoMing Zhang, Chunrui Bo, Ming Bai, Shuang Li, Yang Jiao, Lihua Wang. Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis. Medicine 2022; 101(11) doi: 10.1097/MD.0000000000029107
|
| 2 |
Saurabh Srivastava, Amit Gupta, Deepak Sharma, Anuj Maheshwari, Nadima Shaikeh, Rakesh Sahay, Noel C Barengo. Effect of glucagon on lipid metabolism. Journal of Diabetology 2023; 14(Supplement 1): S25 doi: 10.4103/jod.jod_99_23
|
| 3 |
Tao Zhang, Yingli Nie, Jiliang Wang. The emerging significance of mitochondrial targeted strategies in NAFLD treatment. Life Sciences 2023; 329: 121943 doi: 10.1016/j.lfs.2023.121943
|
| 4 |
Nicholas W. S. Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin, Kris V. Kowdley. Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update. Seminars in Liver Disease 2022; 42(03): 379 doi: 10.1055/a-1877-9656
|
| 5 |
Haoran Jiang, Linquan Zang. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD. Current Pharmaceutical Design 2024; 30(2): 100 doi: 10.2174/0113816128283153231226103218
|
| 6 |
Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH. Current Topics in Medicinal Chemistry 2023; 23(21): 2027 doi: 10.2174/1568026623666230714113808
|
| 7 |
Hsin-Hsien Yu, Hao-Chen Wang, Mao-Chih Hsieh, Ming-Che Lee, Bor-Chyuan Su, Yan-Shen Shan, Si Qin. Exendin‐4 Attenuates Hepatic Steatosis by Promoting the Autophagy‐Lysosomal Pathway. BioMed Research International 2022; 2022(1) doi: 10.1155/2022/4246086
|
| 8 |
Zhiyu Li, Chao Cui, Liang Xu, Mingfeng Ding, Yinghui Wang. Metformin suppresses metabolic dysfunction-associated fatty liver disease by ferroptosis and apoptosis via activation of oxidative stress. Free Radical Research 2024; 58(11): 686 doi: 10.1080/10715762.2024.2417279
|
| 9 |
Masoud Nouri-Vaskeh, Neda Khalili, Amirreza Khalaji, Pouya Behnam, Leila Alizadeh, Sara Ebrahimi, Neda Gilani, Mehdi Mohammadi, Seyed Alisalar Madinehzadeh, Mohammad Zarei. Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. Archives of Physiology and Biochemistry 2023; 129(2): 373 doi: 10.1080/13813455.2020.1828479
|
| 10 |
Eun Ran Kim, Jeong Su Park, Jin Hee Kim, Ji Young Oh, In Jeong Oh, Da Hyun Choi, Yu seol Lee, I. Seul Park, SeungWon Kim, Da Hyun Lee, Jae Hee Cheon, Jin‐Woo Bae, Minyoung Lee, Jin Won Cho, In Bok An, Eun Joo Nam, Sang‐In Yang, Myung‐Shik Lee, Soo Han Bae, Yong‐ho Lee. A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome. Hepatology 2022; 75(6): 1523 doi: 10.1002/hep.32235
|
| 11 |
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01119-3
|
| 12 |
Qin Pan, Jian-Gao Fan, Yusuf Yilmaz. Pathogenetic Pathways in Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2023; 27(2): 317 doi: 10.1016/j.cld.2023.01.013
|